Agenus (AGEN) to Release Quarterly Earnings on Tuesday

Agenus (NASDAQ:AGEN) is anticipated to post its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect Agenus to post earnings of $2.63 per share and revenue of $80.3870 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 11, 2025 at 8:30 AM ET.

Agenus (NASDAQ:AGEN) last issued its earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.22). The firm had revenue of $25.70 million for the quarter, compared to analyst estimates of $49.71 million. On average, analysts expect Agenus to post $-13 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Agenus Price Performance

Shares of Agenus stock traded down $0.20 during trading on Tuesday, hitting $3.77. 112,990 shares of the company’s stock traded hands, compared to its average volume of 729,878. The firm’s fifty day moving average price is $4.22 and its 200 day moving average price is $4.44. Agenus has a twelve month low of $1.38 and a twelve month high of $7.34. The company has a market cap of $120.25 million, a PE ratio of -0.53 and a beta of 1.43.

Analysts Set New Price Targets

Several brokerages recently issued reports on AGEN. Wall Street Zen downgraded shares of Agenus from a “buy” rating to a “hold” rating in a report on Sunday, August 17th. HC Wainwright reissued a “buy” rating on shares of Agenus in a report on Monday, October 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Agenus in a report on Wednesday, October 8th. Finally, Zacks Research raised shares of Agenus to a “hold” rating in a report on Tuesday, August 12th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Agenus has a consensus rating of “Hold” and an average price target of $14.50.

Hedge Funds Weigh In On Agenus

A number of institutional investors have recently modified their holdings of AGEN. Jump Financial LLC bought a new position in shares of Agenus in the second quarter worth about $55,000. Acadian Asset Management LLC bought a new stake in shares of Agenus during the first quarter worth approximately $58,000. Invesco Ltd. bought a new stake in shares of Agenus during the first quarter worth approximately $88,000. Tower Research Capital LLC TRC raised its stake in shares of Agenus by 265.9% during the second quarter. Tower Research Capital LLC TRC now owns 21,871 shares of the biotechnology company’s stock worth $100,000 after buying an additional 15,893 shares during the last quarter. Finally, Engineers Gate Manager LP bought a new stake in shares of Agenus during the second quarter worth approximately $108,000. 61.46% of the stock is owned by institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.